{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:54:37Z","timestamp":1792702477029,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Nowadays, cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors have been approved for treating metastatic breast cancer and have achieved inspiring curative effects. But some discoveries have indicated that CDK 4\/6 are not the requisite factors in some cell types because CDK2 partly compensates for the inhibition of CDK4\/6. Thus, it is urgent to design CDK2\/4\/6 inhibitors for significantly enhancing their potency. This study aims to explore the mechanism of the binding of CDK2\/4\/6 kinases and their inhibitors to design novel CDK2\/4\/6 inhibitors for significantly enhancing their potency in different kinds of cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A series of 72 disparately functionalized 4-substituted <jats:italic>N<\/jats:italic>-phenylpyrimidin-2-amine derivatives exhibiting potent inhibitor activities against CDK2, CDK4 and CDK6 were collected to apply to this research. The total set of these derivatives was divided into a training set (54 compounds) and a test set (18 compounds). The derivatives were constructed through the sketch molecule module in SYBYL 6.9 software. A Powell gradient algorithm and Tripos force field were used to calculate the minimal structural energy and the minimized structure was used as the initial conformation for molecular docking. By the means of 3D-QSAR models, partial least squares (PLS) analysis, molecular dynamics (MD) simulations and binding free energy calculations, we can find the relationship between structure and biological activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, we used molecular docking, 3D-QSAR and molecular dynamics simulation methods to comprehensively analyze the interaction and structure\u2013activity relationships of 72 new CDK2\/4\/6 inhibitors. We used detailed statistical data to reasonably verify the constructed 3D-QSAR models for three receptors (q<jats:sup>2<\/jats:sup> of CDK2\u2009=\u20090.714, R<jats:sup>2<\/jats:sup><jats:sub>pred<\/jats:sub>\u2009=\u20090.764, q<jats:sup>2<\/jats:sup>\u2009=\u20090.815; R<jats:sup>2<\/jats:sup><jats:sub>pred<\/jats:sub> of CDK4\u2009=\u20090.681, q<jats:sup>2<\/jats:sup>\u2009=\u20090.757; R<jats:sup>2<\/jats:sup><jats:sub>pred<\/jats:sub> of CDK6\u2009=\u20090.674). MD simulations and decomposition energy analysis validated the reasonability of the docking results and identified polar interactions as crucial factors that influence the different bioactivities of the studied inhibitors of CDK2\/4\/6 receptors, especially the electrostatic interactions of Lys33\/35\/43 and Asp145\/158\/163. The nonpolar interaction with Ile10\/12\/19 was also critical for the differing potencies of the CDK2\/4\/6 inhibitors. We concluded that the following probably enhanced the bioactivity against CDK2\/4\/6 kinases: (1) electronegative groups at the N1-position and electropositive and moderate-sized groups at ring E; (2) electrogroups featured at R<jats:sub>2<\/jats:sub>; (3) carbon atoms at the X-position or ring C replaced by a benzene ring; and (4) an electrogroup as R<jats:sub>4<\/jats:sub>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Previous studies, to our knowledge, only utilized a single approach of 3D-QSAR and did not integrate this method with other sophisticated techniques such as molecular dynamics simulations to discover new potential inhibitors of CDK2, CDK4, or CDK6. So we applied the intergenerational technology, such as 3D-QSAR technology, molecular docking simulation techniques, molecular dynamics simulations and MMPBSA19\/MMGBSA20-binding free energy calculations to statistically explore the correlations between the structure with biological activities. The constructed 3D-QSAR models of the three receptors were reasonable and confirmed by the excellent statistical data. We hope the results obtained from this work will provide some useful references for the development of novel CDK2\/4\/6 inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05818-y","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:01:41Z","timestamp":1718017301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2\/4\/6"],"prefix":"10.1007","volume":"150","author":[{"given":"Jia-Dong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-E","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"13","key":"5818_CR1","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.3390\/molecules26133923","volume":"26","author":"A Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman A, Shaban A, Nassar I et al (2021) Discovery of new pyrazolopyridine, furopyridine, and pyridine derivatives as CDK2 inhibitors: design, synthesis, docking studies, and anti-proliferative activity. Molecules (basel, Switzerland). 26(13):3923","journal-title":"Molecules (basel, Switzerland)."},{"issue":"9","key":"5818_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/molecules25092031","volume":"25","author":"T Al-Warhi","year":"2020","unstructured":"Al-Warhi T, El Kerdawy AM, Aljaeed N et al (2020) Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors. Molecules 25(9):2031","journal-title":"Molecules"},{"issue":"5","key":"5818_CR3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3390\/molecules26051488","volume":"26","author":"A Ammazzalorso","year":"2021","unstructured":"Ammazzalorso A, Agamennone M, De Filippis B, Fantacuzzi M (2021) Development of CDK4\/6 inhibitors: a five years update. Molecules (basel, Switzerland). 26(5):1488","journal-title":"Molecules (basel, Switzerland)."},{"issue":"12","key":"5818_CR4","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","volume":"186","author":"M Arora","year":"2023","unstructured":"Arora M, Moser J, Hoffman T et al (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 186(12):2628-2643.e2621","journal-title":"Cell"},{"issue":"7","key":"5818_CR5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamaoncol.2022.1059","volume":"8","author":"J Blohmer","year":"2022","unstructured":"Blohmer J, Link T, Reinisch M et al (2022) Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: the GeparX 2 \u00d7 2 randomized clinical trial. JAMA Oncol 8(7):1010\u20131018","journal-title":"JAMA Oncol"},{"issue":"5","key":"5818_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","volume":"31","author":"M Bury","year":"2021","unstructured":"Bury M, Le Calv\u00e9 B, Ferbeyre G, Blank V, Lessard F (2021) New insights into CDK regulators: novel opportunities for cancer therapy. Trends Cell Biol 31(5):331\u2013344","journal-title":"Trends Cell Biol"},{"issue":"16","key":"5818_CR7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case DA, Cheatham TE, Darden T et al (2005) The Amber biomolecular simulation programs. J Comput Chem 26(16):1668\u20131688","journal-title":"J Comput Chem"},{"key":"5818_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.132129","volume":"459","author":"M Chatterjee","year":"2023","unstructured":"Chatterjee M, Roy K (2023) \u201cData fusion\u201d quantitative read-across structure-activity-activity relationships (q-RASAARs) for the prediction of toxicities of binary and ternary antibiotic mixtures toward three bacterial species. J Hazard Mater 459:132129","journal-title":"J Hazard Mater"},{"key":"5818_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.132358","volume":"460","author":"M Chatterjee","year":"2023","unstructured":"Chatterjee M, Banerjee A, Tosi S, Carnesecchi E, Benfenati E, Roy K (2023) Machine learning - based q-RASAR modeling to predict acute contact toxicity of binary organic pesticide mixtures in honey bees. J Hazard Mater 460:132358","journal-title":"J Hazard Mater"},{"issue":"4","key":"5818_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1039\/C5MB00860C","volume":"12","author":"TA Chohan","year":"2016","unstructured":"Chohan TA, Chen J-J, Qian H-Y, Pan Y-L, Chen J-Z (2016) Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Mol Biosyst 12(4):1250\u20131268","journal-title":"Mol Biosyst"},{"issue":"3","key":"5818_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley D, Robinson T, Feng F, Ashworth A (2020) Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov 10(3):351\u2013370","journal-title":"Cancer Discov"},{"issue":"7969","key":"5818_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-023-06274-3","volume":"619","author":"JA Cornwell","year":"2023","unstructured":"Cornwell JA, Crncec A, Afifi MM, Tang K, Amin R, Cappell SD (2023) Loss of CDK4\/6 activity in S\/G2 phase leads to cell cycle reversal. Nature 619(7969):363\u2013370","journal-title":"Nature"},{"issue":"10","key":"5818_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook K, Hoffman R, Miller N et al (2021) Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell 39(10):1404-1421.e1411","journal-title":"Cancer Cell"},{"issue":"6","key":"5818_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ (2022) Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 22(6):356\u2013372","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"5818_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","volume":"20","author":"A Golbraikh","year":"2002","unstructured":"Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Model 20(4):269\u2013276","journal-title":"J Mol Graph Model"},{"issue":"6","key":"5818_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaoncol.2022.7949","volume":"9","author":"T Haddad","year":"2023","unstructured":"Haddad T, Suman V, D\u2019Assoro A et al (2023) Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial. JAMA Oncol 9(6):815\u2013824","journal-title":"JAMA Oncol"},{"issue":"2","key":"5818_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC (2024) The CDK4\/6 inhibitor revolution\u2014a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21(2):89\u2013105","journal-title":"Nat Rev Clin Oncol"},{"key":"5818_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2212304","volume":"41","author":"M Moussaoui","year":"2023","unstructured":"Moussaoui M, Baassi M, Baammi S et al (2023) In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies. J Biomol Struct Dyn 41:1\u201317","journal-title":"J Biomol Struct Dyn"},{"key":"5818_CR19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-030222-120000","author":"JM Paggi","year":"2024","unstructured":"Paggi JM, Pandit A, Dror RO (2024) The art and science of molecular docking. Annu Rev Biochem. https:\/\/doi.org\/10.1146\/annurev-biochem-030222-120000","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"5818_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","volume":"80","author":"S Rubin","year":"2020","unstructured":"Rubin S, Sage J, Skotheim J (2020) Integrating old and new paradigms of G1\/S control. Mol Cell 80(2):183\u2013192","journal-title":"Mol Cell"},{"issue":"5","key":"5818_CR21","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acs.jmedchem.6b01670","volume":"60","author":"S Tadesse","year":"2017","unstructured":"Tadesse S, Yu M, Mekonnen LB et al (2017a) Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. J Med Chem 60(5):1892\u20131915","journal-title":"J Med Chem"},{"issue":"13","key":"5818_CR22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.4155\/fmc-2017-0076","volume":"9","author":"S Tadesse","year":"2017","unstructured":"Tadesse S, Zhu G, Mekonnen LB et al (2017b) A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4\/6 inhibitors. Future Med Chem 9(13):1495\u20131506","journal-title":"Future Med Chem"},{"issue":"12","key":"5818_CR23","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/bph.13974","volume":"175","author":"S Tadesse","year":"2018","unstructured":"Tadesse S, Bantie L, Tomusange K et al (2018) Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. Br J Pharmacol 175(12):2399\u20132413","journal-title":"Br J Pharmacol"},{"issue":"2","key":"5818_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"S Tadesse","year":"2020","unstructured":"Tadesse S, Anshabo A, Portman N et al (2020) Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today 25(2):406\u2013413","journal-title":"Drug Discov Today"},{"issue":"6","key":"5818_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"S Tolaney","year":"2020","unstructured":"Tolaney S, Wardley A, Zambelli S et al (2020) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 21(6):763\u2013775","journal-title":"Lancet Oncol"},{"key":"5818_CR26","doi-asserted-by":"publisher","first-page":"16504","DOI":"10.1021\/acs.jafc.3c05223","volume":"71","author":"Z Yu","year":"2023","unstructured":"Yu Z, Huang Y, Cheng J et al (2023) Spodoptera frugiperda3D-QSAR combination with molecular dynamics simulations to effectively design the active ryanodine receptor agonists against. J Agric Food Chem 71:16504\u201316520","journal-title":"J Agric Food Chem"},{"issue":"4","key":"5818_CR27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00432-022-04135-6","volume":"149","author":"M Zabihi","year":"2023","unstructured":"Zabihi M, Lotfi R, Yousefi A-M, Bashash D (2023) Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities. J Cancer Res Clin Oncol 149(4):1585\u20131606","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"5818_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093704","volume":"9","author":"J Zheng","year":"2014","unstructured":"Zheng J, Kong H, Wilson JM et al (2014) Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking. PLoS ONE 9(4):e93704","journal-title":"PLoS ONE"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05818-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05818-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05818-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:53:05Z","timestamp":1720522385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05818-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["5818"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05818-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"302"}}